Meeting
2024 ASCO Annual Meeting
SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.
Presenter
Andre Rashad Kydd, MD, PhD
Genitourinary Malignancies Branch, CCR, NCI, NIH
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Other GU Kidney and Bladder Cancer
Clinical Trial Registration Number
NCT06161532
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS4627)
DOI
10.1200/JCO.2024.42.16_suppl.TPS4627
Abstract #
TPS4627
Poster Bd #
312a
Abstract Disclosures
Similar Videos & Slides
Speaker: Suzanne Louise Topalian, MD
Speaker: Gordon J. Freeman, PhD
Speaker: Timothy Jerome Moynihan, MD
Videos & Slides
2024 ASCO Annual Meeting
A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.
Speaker: Fernando Cotait Maluf, MD